ClinicalTrials.gg
CompletedNCT01169818ATLASUpdated Jul 8, 2013

Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus

A Phase 4 interventional study of Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 6 sites in 6 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-08.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
555
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
37th of 175
555 · median 253
Started
2010
with 12 others
Phase 4
103 of 176
2 open now
Registered
83rd of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2010, is one of 103 in phase 4, and was the 83rd registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To compare patient-led titration (intervention group) versus physician-led titration (usual standard of care) in optimizing the clinical use of insulin glargine in an Asian population of patients with Type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetic drugs (OADs).

Secondary Objectives:

To determine the difference in glycemic control, safety, quality of life and treatment satisfaction between patient-led titration and usual care.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with T2DM duration of T2DM > 2 years
  2. Insulin naïve
  3. Continuous treatment with stable doses of 2 OADs (sulphonylureas, biguanides, alpha-glucosidase inhibitors, DPP-IV inhibitors, and glinides) for > three months prior to randomization
  4. levels 7% and 11 %
  5. (BMI) 20 and 40 kg/m2
  6. Willing and able to perform blood glucose monitoring using a blood glucose meter

Exclusion criteria

Exclusion criteria:

  1. Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agent intake),
  2. Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for \< 1 week),
  3. Current treatment with thiazolidinediones,
  4. Current or previous use (within the last 3 months) of GLP-1 receptor agonists or GLP-1 analogues,
  5. Current or previous (within the last 3 months) use of any treatment for weight lost,
  6. Active proliferative diabetic retinopathy,
  7. Patient without any history of eye examination in the past 6 months,
  8. Treatment with systemic in the 3 months prior to study entry,
  9. Currently receiving treatment with monoamine oxidase inhibitors,
  10. Currently receiving treatment with non-selective -blockers,
  11. Treatment with any product and/or device in the 2 months prior to study entry,
  12. Likelihood of requiring treatment during the study period with drugs not permitted by the clinical trial protocol,
  13. History of ketoacidosis or hyperosmolar hyperglycemic state,
  14. History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months,
  15. History of congestive heart failure,
  16. History of hypoglycemia unawareness,
  17. Unexplained hypoglycemia in the past 6 months,
  18. Impaired renal function defined as, but not limited to, serum creatinine 1.5 mg/dL (133 mol/L) males or 1.4 mg/dL (124 mol/L) females or presence of macroproteinuria (>2gr/day),
  19. Active liver disease ( ALAT greater than two times the upper limit of the reference range, as defined by the local laboratory),
  20. Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol,
  21. Had a blood transfusion or severe blood loss within the 3 months before screening, or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia,
  22. Known / intolerance to insulin glargine or any of its ,
  23. History of pancreatitis,
  24. Currently undergoing therapy or planned radiological examinations requiring the administration of contrasting agents for (other than non- / early stage basal cell or squamous cell carcinoma),
  25. Pregnant or lactating women (women of must have a negative pregnancy test at study entry and a medically approved method),
  26. Any medical condition that may have an influence on rate.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
555 participants (actual)

Study arms

  • Experimental
    Intervention group

    Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days

    Drug: Insulin Glargine

  • Active comparator
    Usual standard of care group

    Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician

    Drug: Insulin Glargine

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target

    Also known as: Solostar

06

What researchers measure

Primary outcomes

  1. Change (decrease) in mean hemoglobin glycosylated (HbA1c) level

    Time frame: from week 0 (baseline) to week 24 (end of study)

Secondary outcomes

  1. Percentage of patients achieving HbA1c levels < 7.0% without experiencing severe hypoglycemia

    Time frame: from week 0 (baseline) to week 24 (end of study)

  2. Percentage of patients achieving target HbA1c levels (< 7.0% and <6.5%)

    Time frame: from week 0 (baseline) to week 24 (end of study)

  3. Number of patients having a drop of 1% in HbA1c levels and/or a drop of at least 0.5%.

    Time frame: from week 0 (baseline) to week 24 (end of study)

  4. Mean change in Fasting Plasma glucose (FPG) and Post Prandial blood Glucose (PPG)

    Time frame: from week 0 (baseline) to week 24 (end of study)

  5. Evolution of Blood Glucose profiles

    Time frame: from week 0 (baseline) to week 24 (end of study)

  6. Incidence of symptomatic hypoglycemia

    Time frame: from week 0 (baseline) to week 24 (end of study)

  7. Incidence of nocturnal hypoglycemia

    Time frame: from week 0 (baseline) to week 24 (end of study)

  8. Incidence of asymptomatic hypoglycemia

    Time frame: from week 0 (baseline) to week 24 (end of study)

  9. Mean change in body weight in patients

    Time frame: from week 0 (baseline) to week 24 (end of study)

  10. Mean insulin dose

    Time frame: from week 0 (baseline) to week 24 (end of study)

  11. PROMs (patient reported outcome measures) scores from the DTSQs/c (diabetes treatment satisfaction questionnaire status) and EQ-5D (European quality of life - 5 dimensions)

    Time frame: from week 0 (baseline) to week 24 (end of study)

07

Study locations

6 sites
  • Administrative office
    Shanghai, China
  • Administrative office
    Mumbai, India
  • Administrative office
    Tokyo, Japan
  • Administrative office
    Karachi, Pakistan
  • Administrative office
    Makati City, Philippines
  • Administrative office
    Moscow, Russian Federation
08

References and documents

Publications

  • ATLAS Study Group. Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS). Diabetes Technol Ther. 2011 Jan;13(1):67-72. doi: 10.1089/dia.2010.0170. PubMed 21175274 ↗
  • Garg SK, Admane K, Freemantle N, Odawara M, Pan CY, Misra A, Jarek-Martynowa IR, Abbas-Raza S, Mirasol RC, Perfetti R. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015 Feb;21(2):143-57. doi: 10.4158/EP14079.OR. PubMed 25297660 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2010
First posted
Jul 26, 2010
Start
Aug 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Jul 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01169818
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 26, 2010
Start date
Aug 2010
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Jul 8, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion